Testing CAR-T cell therapy for severe lupus
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of immunotherapy called CAR-T cell therapy for people with severe lupus that hasn't improved with usual treatments. The therapy uses your own immune cells to target and reduce the abnormal immune response that causes lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 50.
- Diagnosed with systemic lupus erythematosus (SLE, also called lupus).
- Active lupus despite trying at least two standard treatments (like steroids, methotrexate, or rituximab).
- Adequate organ function (heart, lungs, liver, kidneys, blood counts).
- Agree to use effective contraception during and for 12 months after treatment.
- No serious heart or lung conditions, active infections, cancer history, or prior organ/stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
This trial tests an experimental therapy called IC19 CAR-T cells, which are specially modified immune cells, for people with severe lupus that hasn't gotten better with standard treatments. The goal is to see if this therapy can calm the immune system and reduce lupus symptoms.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.